Aspira Women's Health Inc. (AWHL): Total Liabilities
$12.39M
As of 2025-12-31
$11.69M
As of 2026-06-30
+6.0%
3-year compound annual growth
+4.6%
5-year compound annual growth
+13.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.39M | +53.8% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $8.05M | -6.6% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $8.63M | -17.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $10.39M | n/a | 2024-04-01, Balance as of period end |
| 2022-09-30 | $12.76M | n/a | 2023-10-26, Balance as of period end |
| 2021-12-31 | $10.91M | +10.3% | 2023-10-26, Balance as of period end |
| 2020-12-31 | $9.89M | +94.2% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $5.09M | +19.6% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $4.26M | +4.1% | 2020-04-07, Balance as of period end |
| 2017-12-31 | $4.09M | -3.9% | 2019-03-28, Balance as of period end |
| 2016-12-31 | $4.26M | +24.7% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $3.41M | -30.6% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $4.92M | +27.0% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $3.87M | -2.3% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $3.97M | -68.9% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $12.75M | -34.3% | 2013-03-01, Balance as of period end |
| 2010-12-31 | $19.42M | n/a | 2012-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $42.49M | +19.7% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $55.82M | +23.1% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
Compare AWHL, NNNN, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗